Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

ety profile of this triplet regimen and to lay the groundwork for a potential larger Phase 2/3 trial. We expect to start our Phase 2 monotherapy trial in newly-diagnosed HER2-positive patients later this year. We believe that the clinical activity of alvespimycin seen in our breast cancer Phase 1 trials to date validates the compound's therapeutic potential as a novel anticancer agent and strengthens Kosan's leadership in the Hsp90 inhibitor area."

Phase 1 Updated Results

Alvespimycin is a second-generation Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key signaling pathway in breast cancer.

Preliminary results from the Phase 1 trial of alvespimycin in combination with trastuzumab were presented at the 2007 ASCO annual meeting in June, and were updated in this presentation. The Phase 1 trial was designed to identify the recommended Phase 2 dose through the evaluation of toxicity and activity in patients with solid tumors. Patients were enrolled in three dose cohorts. The dosing schedule for alvespimycin was a one-hour weekly intravenous infusion of 60, 80 or 100 mg/m2 administered along with the standard dose of trastuzumab. Patients were assessed every 4 weeks for toxicity and every 8 weeks for response. Disease response was assessed by RECIST and by tumor markers, if available.

Of the 27 heavily-pretreated patients enrolled in the trial, 24 patients had HER2-positive breast cancer (with the majority of patients having had multiple trastuzumab-containing regimens prior to this study) and 3 patients had ovarian cancer (HER2 status unknown).

Clinical benefit was observed in 42% of evaluable patients (8 of 19 evaluable) with HER2-positive metastatic breast cancer:

-- 1 patient (13 prior regimens, including progression on single-agent

lapatinib and 3 prior trastuzumab-containing regimens) showed compl
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... BEIJING, May 17, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical ... or the "Company"), an emerging leader in the development, ... medical products, today announced that the Company will present ... be held at the Shanghai Purple Mountain Hotel in ...
... Simbionix USA Corporation, the world,s leading provider ... proud to announce the release two new platform ... Express simulator and the enhanced hardware for ... (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a) ,     (Photo: ...
Cached Medicine Technology:Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events 2
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... 12, 2014 Utah Valley Entrepreneurial Forum ... with awards being bestowed to companies in revenue, and ... entrepreneur community with recognition for new ideas as well ... incoming revenue. , 25 Under 5 highlights outstanding Utah ... are under 5 years old. Award recipients were recognized ...
(Date:7/12/2014)... Texas (PRWEB) July 12, 2014 ... Breastfeeding Made Simple as a valuable new resource for ... roughly two-thirds of American women work away from their ... sources touting the benefits of breastfeeding, but often feel ... to nurse their babies. With its evidence-based insights, and ...
(Date:7/12/2014)... Angeles, CA (PRWEB) July 12, 2014 ... buyer power score of 4.1 out of 5. ... market that have been underpinning buyer negotiation power ... IBISWorld procurement analyst Anna Son, “during the period, ... with rising costs associated with new product development, ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, the trendy ... an affordable gown can visit Discount-Dress.com (a reliable ... dream items. Recently, the company has announced its new selection ... that, it is also providing great discounts for these unique ... of this promotion is July 29, 2014. , Discount-Dress.com ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... Bacteria that live in the sub-gingival plaques can increase the ... is published in the current issue of Journal of Periodontology, ... an acute myocardial infarction or heart attack are also the ... plaques were higher than the rest of the participants of ...
... condition of anorexia nervosa and got cured,// often may have ... harmful health condition, the increased body fat does not get ... the body fat often gets deposited in an abnormal way, ... an eating disorder characterized by purposeful weight loss that is ...
... is the commonest cancer effecting men. Benefits of Lycophene- ... and pink grapefruit( most lycopene in processed tomato products ... sometime in preventing the aging process and improve ... now being looked at for preventing and treating cancers ...
... of thyroid cancer may be detectable using a blood ... to a study published by researchers at The ... G. James Cancer Hospital and Richard J. Solove Research ... in the Journal of Clinical Endocrinology & Metabolism. ...
... rinse solution can be of help to decide how far ... mouth rinse of the patients of bone marrow transplant can ... that fight infection in the body. Patients of bone marrow ... of mucositis that may be caused by their treatment procedure. ...
... and linked to the human genetic// makeup. ,Researchers ... Foxp2 gene is found in one of the regions ... autism, and specific language impairment that can cause communication ... engineered mice with Foxp2 gene mutations, results demonstrate that ...
Cached Medicine News:Health News:Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available 2
The perfect tool to prepare for in-service or licensing exams, for recertification, or for use as a clinical refresher....
... Sun Med TruFlow™ Oxygen flowmeter with ... lifetime warranty covering calibration and manufacturing defects. ... to meet most needs. Also available with ... auxiliary power take-off and double unit configurations. ...
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: